Sunil Parimi
Overview
Explore the profile of Sunil Parimi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
75
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Fonseca N, Maurice-Dror C, Herberts C, Tu W, Fan W, Murtha A, et al.
Nat Commun
. 2024 Feb;
15(1):1828.
PMID: 38418825
No consensus strategies exist for prognosticating metastatic castration-resistant prostate cancer (mCRPC). Circulating tumor DNA fraction (ctDNA%) is increasingly reported by commercial and laboratory tests but its utility for risk stratification...
2.
Yip S, Morash C, Kolinsky M, Kapoor A, Ong M, Selvarajah S, et al.
Can Urol Assoc J
. 2023 Jul;
17(10):326-336.
PMID: 37494316
Introduction: In patients with prostate cancer (PCa), the identification of an alteration in genes associated with homologous recombination repair (HRR) has implications for prognostication, optimization of therapy, and familial risk...
3.
Ko J, Adams J, McMillan T, Sunderland K, Goulart J, Rauw J, et al.
Can Urol Assoc J
. 2022 Jun;
16(11):E528-E532.
PMID: 35704939
Introduction: Unresectable and metastatic small cell carcinoma of the prostate (SCPC) is a rare and aggressive disease that is under-represented in clinical trials. We carried out a retrospective chart review...
4.
Parimi S, Bondy S, Tsang E, McKenzie M, Bachand F, Aparicio M, et al.
Can Urol Assoc J
. 2019 Aug;
13(10):E311-E316.
PMID: 31364977
Introduction: Clinical trials have shown that radium-223 (Ra223) can prolong survival and improve quality of life in patients with metastatic castration-resistant prostate cancer (mCRPC). The objectives of this study were...
5.
Chedgy E, Vandekerkhove G, Herberts C, Annala M, Donoghue A, Sigouros M, et al.
J Pathol
. 2018 Jul;
246(2):244-253.
PMID: 30015382
Small-cell prostate carcinoma (SCPC) is an aggressive malignancy that is managed similarly to small-cell lung cancer. SCPC can evolve from prostate adenocarcinoma in response to androgen deprivation therapy, but, in...
6.
Parimi S, Tsang E, Alexander A, Mckenzie M, Bachand F, Sunderland K, et al.
Can Urol Assoc J
. 2018 Feb;
11(10):350-355.
PMID: 29382449
Introduction: Radium 223 (Ra223) given for six cycles has proven efficacy in clinical trials, but its population-level generalizability has not been well-described. The objectives of this study were to describe...
7.
Nixon N, Khan O, Imam H, Tang P, Monzon J, Li H, et al.
Cancer
. 2017 Aug;
123(23):4672-4679.
PMID: 28817175
Background: Understanding the drug development pathway is critical for streamlining the development of effective cancer treatments. The objective of the current study was to delineate the drug development timeline and...
8.
Ezeife D, Parimi S, Cusano E, Smith M, Truong T, Raissouni S, et al.
J Natl Compr Canc Netw
. 2017 Aug;
15(8):1005-1013.
PMID: 28784862
Phase III trials in metastatic colorectal cancer (mCRC) have collectively led to progressive advancements in patient outcomes over the past decades. This study characterizes the evolution of mCRC phase III...
9.
Recent advances in circulating tumor cells and cell-free DNA in metastatic prostate cancer: a review
Parimi S, Ko J
Expert Rev Anticancer Ther
. 2017 Jul;
17(10):939-949.
PMID: 28737470
The treatment landscape of metastatic prostate cancer has changed dramatically over the past five years. As new discoveries are made and further novel therapies become available, there is a heightened...
10.
Parimi S, Eliasziw M, North S, Trudeau M, Winquist E, Chi K, et al.
Invest New Drugs
. 2016 Aug;
34(6):771-776.
PMID: 27565809
Background Docetaxel is a standard first-line treatment option for men with metastatic castration resistant prostate cancer (mCRPC). Sunitinib is attractive as a maintenance therapy due to its mechanism of action,...